NZ537004A

NZ537004A - N-benzoylureidocinnamate derivatives, method for production and use thereof

Info

Publication number: NZ537004A
Application number: NZ537004A
Authority: NZ
Inventors: Karl Schoenafinger; Elisabeth Defossa; Dieter Kadereit; Erich Von Roedern; Thomas Klabunde; Hans-Joerg Burger; Andreas Herling; Karl-Ulrich Wendt
Original assignee: Sanofi Aventis Deutschland
Priority date: 2002-06-07
Filing date: 2003-05-22
Publication date: 2006-06-30
Also published as: DK1513800T3; CY1106003T1; ES2277082T3; EP1513800B1; HRP20041161A2; BR0311646A; AU2003238373A1; PT1513800E; DE10225635C1; TW200404763A; NO20050087L; CA2488760A1; MA27232A1; MXPA04011984A; DE50305693D1; HRPK20041161B3; ZA200408887B; JP4398859B2; WO2003104188A1; RU2004139122A

Abstract

N-benzoylureidocinnamic acid derivatives of formula (I), the physiologically acceptable salts and method for production thereof are disclosed, wherein R1-R11 are as defined in the specification. These compounds are suitable as an anti-diabetic agent.

Description

<div class="application article clearfix" id="description"> New Zealand Paient Spedficaiion for Paient Number 537004 537004 WO 03/104188 1 PCT/EP03/05355 Description N-Benzoylureidocinnamic acid derivatives, processes for preparing them 5 and their use The invention relates to N-benzoylureidocinnamic acid derivatives and to their physiologically tolerated salts and physiologically functional derivatives. 0 EP 0 193 249 (Duphar) describes acylcarboxyphenylurea derivatives which possess antitumor activity. The invention was based on the object of providing compounds which can 15 be used for preventing and treating type 2 diabetes. In this respect, the compounds should considerably lower the blood sugar level. The invention therefore relates to compounds of the formula I, 20 R3 in which O O (^j\_ VPyW /\ 1 1 R6 YX R1 r2 R9 R10 R11 R5 Intellectual Property Office of N.Z. - 3 DEC 20M received R7, R8, R9 and R10 are, independently of each other, H, F, CI, Br, OH, 25 N02, CN, 0-(CrC6)-alkyl, 0-(C2-C6)-alkenyl, 0-(C2-C6)- alkynyl, 0-S02-(Ci-C4)-alkyl, (CrC6)-alkyl, (C2-C6)-alkenyl or (C2-C6)-alkynyl, where alkyl, alkenyl and alkynyl can be substituted, more than once, by F, CI or Br; 30 R1 and R2 are, independently of each other, H, (Ci-C6)-alkyl, where alkyl can be substituted by OH, 0-(CrC4)-alkyl, NH2, NH(CrC4)- 2 alkyl or N[(Ci-C6)-alkyl]2, 0-(CrC6)-alkyl, CO-(CrC6)-alkyl, COO-(Ci-C6)-alkyl, (CrC6)-alkylene-COOH or (Ci-C6)-alkylene-COO-(CrC6)-alkyl; R3, R4, R5 and R6 are, independently of each other, H, F, CI, Br, N02, CN, 0-R12, S-R12, COOR12, N(R13)(R14), N(R13)COR15, (CrC6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, (C3-C7)-cycloalkyl or (C3-C7)-cycloalkyl-(CrC4)-alkylene, where alkyl, cycloalkyl, alkylene, alkenyl and alkynyl can be substituted, more than once, by F, CI, Br, OR12, COOR12 or N(R16)(R17); R11 is OR12 or N(R18)(R19); R12 is H, (CrCsJ-alkyl, (C2-C8)-alkenyl, (C2-C8)-alkynyl, where alkyl, alkenyl and alkynyl can be substituted, more than once, by F, CI, Br, OH or 0-(Ci-C4)-alkyl; R13 and R14 are, independently of each other, H, (CrC8)-alkyl, (C2-C8)-alkenyl, (C2-C8)-alkynyl, (C3-C7)-cycloalkyl, (C3-C7)-cycloalkyl-(CrC4)-alkylene, COO-(Ci-C4)-alkyl, COO-(C2-C4)-alkenyl, phenyl or S02-phenyl, where the phenyl ring can be substituted, up to two times, by F, CI, CN, OH, (CrC6)-alkyl, 0-(CrC6)-alkyl, CF3, OCF3, COOH, COO-(CrC6)-alkyl or CONH2; or the radicals R13 and R14 form, with the nitrogen atom to which they are bonded, a 3-7-membered, saturated heterocyclic ring which can contain up to 2 further heteroatoms from the group N, O or S, where the heterocyclic ring can be substituted, up to three times, by F, CI, Br, OH, Oxo, N(R20)(R21) or (CrC4)-alkyl; R16 and R17are, independently of each other, H, (C-i-CsJ-alkyl, (C2-Cs)-alkenyl, (C2-C8)-alkynyl, (C3-C7)-cycloalkyl, (C3-C7)-cycloalkyl-(CrC4)-alkylene, COO-(CrC4)-alkyl, COO-(C2-C4)-alkenyl, phenyl or S02-phenyl, where the phenyl ring can be substituted, up to two times, by F, CI, CN, OH, (CrC6)-alkyl, 0-(CrC6)-alkyl, CF3, OCF3, COOH, COO-(CrC6)-alkyl or 3 CONH2; or the radicals R16 and R17 form, with the nitrogen atom to which they are bonded, a 3-7-membered, saturated heterocyclic ring which 5 can contain up to 2 further heteroatoms from the group N, O or S, where the heterocyclic ring can be substituted, up to three times, by F, CI, Br, OH, Oxo, N(R20)(R21) or (CrC4)-alkyl. 10 R18, R19 are, independently of each other, H, (CrCs)-alkyI, (C2-C8)-alkenyl, (C2-Ce)-alkynyl, (C3-C7)-cycloalkyl, (C3-C7)-cycloalkyl-(CrC4)-alkylene, COO-(Ci-C4)-alkyl, COO-(C2-C4)-alkenyl, phenyl or S02-phenyl, where the phenyl ring can be substituted, up to two times, by F, CI, CN, OH, (CrC6)-alkyl, 15 0-(CrC6)-alkyl, CF3, OCF3, COOH, COO-(Ci-C6)-alkyl or CONH2; or the radicals R18 and R19, together with the nitrogen atom to which they are bonded, form a 3-7-membered, saturated heterocyclic ring 20 which can contain up to 2 further heteroatoms from the group N, O or S, where the heterocyclic ring can be substituted, up to three times, by F, CI, Br, OH, Oxo, N(R20)(R21) or (CrC4)-alkyl. #25 / 30 35 Intellectual Property Office of N.2. - 7 JUN 2005 received 4 R15 is (Ci-C8)-alkyl, (C2-C8)-alkenyI, (C2-C8)-alkynyl, (C3-C7)-cyclo- alkyl, (C3-C7)-cycloalkyl-(Ci-C4)-alkylene, where alkyl, cycloalkyl, alkylene, alkenyl and alkynyl can be substituted more than once by F, NH2, NH(CrC4)-alkyl, N[(CrC4)-alkyl]2, OH, 0-(CrC4)-alkyl, 0-(C2-C4)-alkenyl) or 0-C0-(CrC4)-alkyl, COOR12, C0N(R13)(R14), heteroaryl, (C6-Ci0)-aryl or (C6-Cio)-aryl-(CrC4)-alkylene, where heteroaryl and aryl can be substituted by 0-(CrC4)-alkyl, where alkyl can be substituted more than once by F or CI; 10 R20 and R21 are, independently of each other, H, (Ci-C8)-alkyl, (C2-C8)-alkenyl, (C2-C8)-alkynyl, (C3-C7)-cycloalkyl, (C3-C7)-cycloalkyl-(Ci-C4)-alkylene, COO-(CrC4)-alkyl, COO-(C2-C4)-alkenyl, phenyl or S02-phenyl, where the phenyl ring can be 15 substituted, up to two times, by F, CI, CN, OH, (Ci-C6)-alkyl, 0-(Ci-C6)-alkyl, CF3, OCF3, COOH, COO-(CrC6)-alkyl or CONH2; and the physiologically tolerated salts thereof. 20 Preference is given to compounds of the formula I in which one or more radicals have the following meaning: R7, R8, R9 and R10 are, independently of each other, H, F, CI, Br, OH, 25 N02, CN, 0-(Ci-C6)-alkyl, 0-(C2-C6)-alkenyl, 0-(C2-C6)-alkynyl, 0-S02-(Ci-C4)-alkyl, (CrC6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, where alkyl, alkenyl and alkynyl can be substituted, more than once, by F, CI or Br; 30 R1 and R2 are H; R3, R4, R5 and R6 are, independently of each other, H, F, CI, Br, N02, CN, 0-R12, S-R12, COOR12, N(R13)(R14), N(R13)COR15, (CrC6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, (C3-C7)-cyclo-35 alkyl or (C3-C7)-cycloalkyl-(Ci-C4)-alkylene, where alkyl, cycloalkyl, alkylene, alkenyl and alkynyl can be substituted, more than once, by F, CI, Br, OR12, COOR12 or N(R16)(R17); Intellectual Property •f N.Z. 19 SEP 2005 received 5 R11 is 0R12 or N(R18)(R19); R12 is H, (Ci-C8)-alkyl, (C2-C8)-alkenyl, (C2-C8)-alkynyl, where alkyl, alkenyl and alkynyl can be substituted, more than once, by F, 5 CI, Br, OH or 0-(CrC4)-alkyl, R13 and R14 are, independently of each other, H, (CrC8)-alkyl, (C2-C8)-alkenyl, (C2-C8)-alkynyl, (C3-C7)-cycloalkyl, (C3-C7)-cycloalkyl-(CrC4)-alkylene, COO-(CrC4)-alkyl, COO-(C2-C4)-alkenyl, 10 phenyl or S02-phenyl, where the phenyl ring can be substituted, up to two times, by F, CI, CN, OH, (CrC6)-alkyl, 0-(Ci-C6)-alkyl, CF3, OCF3, COOH, COO-(CrC6)-alkyl or CONH2; 15 or the radicals R13 and R14 form, with the nitrogen atom to which they are bonded, a 3-7-membered, saturated heterocyclic ring which can contain up to 2 further heteroatoms from the group N, O or S, where the heterocyclic ring can be substituted, up to three times, by F, CI, Br, OH, Oxo, N(R20)(R21) or 20 (Ci-C4)-alkyl. R16 and R17 are, independently of each other, H, (Ci-C8)-alkyl, (C2-C8)-alkenyl, (C2-C8)-alkynyl, (C3-C7)-cycloalkyl, (C3-C7)-cycloalkyl-(Ci-C4)-alkylene, COO-(CrC4)-alkyl, COO-(C2-C4)-alkenyl, 25 phenyl or S02-phenyl, where the phenyl ring can be substituted, up to two times, by F, CI, CN, OH, (CrC6)-alkyl, 0-(CrC6)-alkyl, CF3, OCF3, COOH, COO-(CrC6)-alkyl or CONH2; 30 or the radicals R16 and R17, together with the nitrogen atom to which they are bonded, form a 3-7-membered, saturated heterocyclic ring which can contain up to 2 further heteroatoms from the group N, O or S, where the heterocyclic ring can be substituted, up to three times, by F, CI, Br, OH, Oxo, N(R20)(R21) or 35 (CrC4)-alkyl. R18 and R19 are, independently of each other, H, (CrC8)-alkyl, (C2-C8)-alkenyl, (C2-C8)-alkynyl, (C3-C7)-cycloalkyl, (C3-C7)-cycloalkyl- 6 (CrC4)-alkylene, COO-(Ci-C4)-alkyl, COO-(C2-C4)-alkenyl, phenyl or S02-phenyl, where the phenyl ring can be substituted, up to two times, by F, CI, CN, OH, (CrC6)-alkyl, 0-(CrC6)-alkyl, CF3, OCF3, COOH, COO-(CrC6)-alkyl or 5 CONH2; or the radicals R18 and R19, together with the nitrogen atom to which they are bonded, form a 3-7-membered, saturated heterocyclic ring which can contain up to 2 further heteroatoms from the group 10 N, O or S, where the heterocyclic ring can be substituted, up to three times, by F, CI, Br, OH, Oxo, N(R20)(R21) or (CrC4)-alkyl. R15 is (CrC8)-alkyl, (C2-C8)-alkenyl, (C2-C8)-alkynyl, (C3-C7)-cyclo- 15 alkyl, (C3-C7)-cycloalkyl-{Ci-C4)-alkylene, where alkyl, cyclo alkyl, alkylene, alkenyl and alkynyl can be substituted more than once by F, NH2, NH(CrC4)-alkyl, N[(Ci-C4)-alkyl]2, OH, 0-(CrC4)-alkyl, 0-(C2-C4)-alkenyl) or 0-C0-(CrC4)-alkyl, COOR12, CON(R13)(R14), heteroaryl, (C6-Ci0)-aryl, (C6-C10)-20 aryl-(Ci-C4)-alkylene, where heteroaryl and aryl can be substituted by 0-(Ci-C4)-alkyl, where alkyl can be substituted more than once by F or CI; R20 and R21 are, independently of each other, H, (Ci-C8)-alkyl, (C2-C8)- 25 Intellectual Pron^r'""" Office of 2 9 MOV 2005 I R E C E i ■, r alkenyl, (C2-C8)-alkynyl, (C3-C7)-cycloalkyl, (C3-C7)-cycloalkyl-(Ci-C4)-alkylene, COO-(Ci-C4)-alkyl, COO-(C2-C4)-alkenyl, phenyl or S02-phenyl, where the phenyl ring can be substituted, up to two times, by F, CI, CN, OH, (CrC6)-alkyl, 5 0-(CrC6)-alkyl, CF3, OCF3, COOH, COO-(Ci-C6)-alkyl or CONH2; and the physiologically tolerated salts thereof. 10 Very particular preference is given to compounds of the formula I in which one or more radicals have the following meaning: R7, R8, R9 and R10 are, independently of each other, H, F or CI; 15 R1 and R2 are H; R3, R4, R5 and R6 are, independently of each other, H, CI, COOH, COO-(CrC4)-alkyl or NHCOR15; 20 R11 is OR12, N(R18)(R19); R12 is H or (CrC4)-alkyl; R18, R19 is H or (Ci-C4)-alkyl; 25 R15 is (CrC4)-alkyl or COOH; and the physiologically tolerated salts thereof. 30 The alkyl radicals in the substituents R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 R12, R13, R14, R15, R16, R17, R18, R19, R20orR21 can be either straight-chain or branched. 35 If radicals or substituents can occur more than once in the compounds of the formula I, such as 0-R12, they can then all, independently of each other, have the given meanings and be identical or different. The invention relates to compounds of the formula I, in the form of their 8 racemates, racemic mixtures and pure enantiomers, and to their diastereomers and mixtures thereof. Because of their higher solubility in water as compared with the starting 5 compounds or basal compounds, pharmaceutical^ tolerated salts are particularly suitable for medical applications. These salts must possess a pharmaceutically tolerated anion or cation. Suitable pharmaceutical^ tolerated acid addition salts of the compounds according to the invention are salts of inorganic acids, such as hydrochloric acid, hydrobromic acid, 10 phosphoric acid, metaphosphoric acid, nitric acid and sulfuric acid, and also of organic acids, such as acetic acid, benzenesulfonic acid, benzoic acid, citric acid, ethanesulfonic acid, fumaric acid, gluconic acid, glycolic acid, isethionic acid, lactic acid, lactobionic acid, maleic acid, malic acid, methanesulfonic acid, succinic acid, p-toluenesulfonic acid and tartaric 15 acid. Suitable pharmaceutically tolerated basic salts are ammonium salts, alkali metal salts (such as sodium salts and potassium salts), alkaline earth metal salts (such as magnesium salts and calcium salts), trometamol (2-amino-2-hydroxymethyl-1,3-propanediol), diethanolamine, lysine or ethylenediamine. 20 Salts which contain an anion which is not pharmaceutically tolerated, such as trifluoroacetate, also belong within the scope of the invention as useful intermediates for preparing or purifying pharmaceutically tolerated salts and/or for use in nontherapeutic, for example in-vitro, applications. 25 The term "physiologically functional derivative" which is used here denotes any physiologically tolerated derivative of a compound according to the invention of the formula I, e.g. an ester which is able, on being administered to a mammal, such as a human, to form (directly or indirectly) 30 a compound of the formula I or an active metabolite thereof. The physiologically functional derivatives also include prodrugs of the compounds according to the invention, as described, for example, in H. Okada et al., Chem. Pharm. Bull, 1994, 42, 57-61. Such prodrugs can be 35 metabolized in vivo to give a compound according to the invention. These prodrugs may or may not themselves be active. The compounds according to the invention can also be present in different polymorphic forms, e.g. as amorphous and crystalline polymorphous forms. 9 All polymorphous forms of the compounds according to the invention belong within the scope of the invention and are another aspect of the invention. 5 In that which follows, all references to "compound(s) according to formula I" refer to compound(s) of the formula I as described above and to their salts, solvates and physiologically functional derivatives as described herein. In another aspect the invention relates to the use of the compound(s) 10 according to formula I for producing a medicament for treating type 2 diabetes. In another aspect the invention relates to the use of the compound(s) according to formula I for producing a medicament for lowering blood sugar. 15 In another aspect the invention relates to the use of the compound(s) according to formula I in combination with at least one further blood sugar-lowering active compound for producing a medicament for treating type 2 diabetes. In another aspect the invention relates to the use of the compound(s) according to formula I in combination with at least one further blood sugar-lowering active compound for producing a medicament for lowering blood sugar. 25 In another aspect the invention relates to a process for producing a pharmaceutical which comprises one or more of the compounds according to formula I, which comprises mixing the active compound with a pharmaceutically suitable excipient and bringing this mixture into a form which is suitable for administration. 30 (followed by page 9A) 20 35 Intellectual Property Office of N.Z. - 7 JUN 2005 received 9A The quantity of a compound according to Formula I which is required in order to achieve the desired biological effect depends on a number of factors, e.g. the specific compound which is selected, the intended use, the nature of administration and the clinical condition of the patient. In general, the daily dose is in the range from 0.3 mg to 100 mg (typically from 3 mg and 50 mg) per day per kilogram of bodyweight, e.g. 3-10 mg/kg/day. An intravenous dose can, for example, be in the range from 0.3 mg to 1.0 mg/kg, which dose can expediently be administered as an infusion of from 10 ng to 100 ng per kilogram per minute. Infusion solutions which are suitable for these purposes can, for example, contain from 0.1 ng to 10 mg, typically from 1 ng to 10 mg, per milliliter. Individual doses can, for example, contain from 1 mg to 10 g of the active compound. Thus, ampoules for injections can, for example, contain from 1 mg to 100 mg, and orally administrable individual dose formulations, such as tablets or capsules, can, for example, contain from 1.0 to 1000 mg, typically from 10 to 600 mg. While, for the therapy of the abovementioned conditions, the compounds according to formula I can be used themselves as compounds, they are preferably present, together with a tolerated excipient, in the form of a pharmaceutical composition. The excipient naturally has to be tolerated in the sense that it is compatible with the other components of the composition and is not harmful to the health of the patient. The excipient can be a solid or a liquid or both and is preferably formulated together with the compound as an individual dose, for example as a tablet, which can contain from 0.05% to 95% by weight of the active compound. Other pharmaceutically active substances can also be present, including other compounds according to formula I. The pharmaceutical compositions according to the invention can be prepared using one of the known pharmaceutical methods, which essentially consist in the constituents being Intellectual Property Office of N.Z. - 7 JUN 2005 received 9 All polymorphous forms of the compounds according to the invention belong within the scope of the invention and are another aspect of the invention. 5 In that which follows, all references to "compound(s) according to formula I" refer to compound(s) of the formula I as described above and to their salts, solvates and physiologically functional derivatives as described herein. The compound(s) of the formula (I) can also be administered in 10 combination with other active compounds. The quantity of a compound according to Formula I which is required in order to achieve the desired biological effect depends on a number of factors, e.g. the specific compound which is selected, the intended use, the 15 nature of administration and the clinical condition of the patient. In general, the daily dose is in the range from 0.3 mg to 100 mg (typically from 3 mg and 50 mg) per day per kilogram of bodyweight, e.g. 3-10 mg/kg/day. An intravenous dose can, for example, be in the range from 0.3 mg to 1.0 mg/kg, which dose can expediently be administered as an infusion of 20 from 10 ng to 100 ng per kilogram per minute. Infusion solutions which are suitable for these purposes can, for example, contain from 0.1 ng to 10 mg, typically from 1 ng to 10 mg, per milliliter. Individual doses can, for example, contain from 1 mg to 10 g of the active compound. Thus, ampoules for injections can, for example, contain from 1 mg to 100 mg, and 25 orally administrable individual dose formulations, such as tablets or capsules, can, for example, contain from 1.0 to 1000 mg, typically from 10 to 600 mg. While, for the therapy of the abovementioned conditions, the compounds according to formula I can be used themselves as compounds, they are preferably present, together with a tolerated excipient, in the form 30 of a pharmaceutical composition. The excipient naturally has to be tolerated in the sense that it is compatible with the other components of the composition and is not harmful to the health of the patient. The excipient can be a solid or a liquid or both and is preferably formulated together with the compound as an individual dose, for example as a tablet, which can 35 contain from 0.05% to 95% by weight of the active compound. Other pharmaceutically active substances can also be present, including other compounds according to formula I. The pharmaceutical compositions according to the invention can be prepared using one of the known pharmaceutical methods, which essentially consist in the constituents being 10 mixed with pharmacologically tolerated excipients and/or auxiliary substances. Pharmaceutical compositions according to the invention are those which 5 are suitable for oral, rectal, topical, peroral (e.g. sublingual) and parenteral (e.g. subcutaneous, intramuscular, intradermal or intravenous) administration, even though the most suitable mode of administration depends, in each individual case, on the nature and severity of the condition to be treated and on the nature of the compound according to 10 formula I which is employed in each case. Coated formulations and coated delayed-release formulations also belong within the scope of the invention. Preference is given to formulations which are acid-resistant and gastric juice-resistant. Suitable gastric juice-resistant coatings include cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethyl 15 cellulose phthalate and anionic polymers of methacrylic acid and methyl methacrylate. Suitable pharmaceutical compounds for oral administration can be present in separate units, such as capsules, cachets, sucking tablets or tablets 20 which in each case contain a defined quantity of the compound according to formula I; as powders or granules; as a solution or suspension in an aqueous or nonaqueous liquid; or as an oil-in-water or water-in-oil emulsion. As already mentioned, these compositions can be prepared using any suitable pharmaceutical method which comprises a step in which 25 the active compound and the excipient (which can be composed of one or more additional constituents) are brought into contact. In general, the compositions are prepared by uniformly and homogeneously mixing the active compound with a liquid and/or finely divided solid excipient, after which the product is molded, if required. Thus, a tablet, for example, can be 30 prepared by pressing or molding a powder or granulate of the compound, where appropriate together with one or more additional constituents. Pressed tablets can be prepared by tableting the compound in freely flowing form, such as a powder or granulate, where appropriate mixed with a binding agent, lubricant, inert diluent and/or a (several) surface-35 active/dispersing agent(s) in a suitable machine. Molded tablets can be prepared by molding the pulverulent compound, which is moistened with an inert liquid diluent, in a suitable machine. Pharmaceutical compositions which are suitable for peroral (sublingual) 11 administration include sucking tablets, which contain a compound according to formula I together with a flavoring agent, usually sucrose and gum arabic or tragacanth, and lozenges, which comprise the compound in an inert base such as gelatin and glycerol or sucrose and gum arabic. 5 Suitable pharmaceutical compositions for parenteral administration preferably include sterile aqueous preparations of a compound according to formula I which are preferably isotonic with the blood of the intended recipient. These preparations are preferably administered intravenously, 10 even though the administration can also take place as an injection subcutaneously, intramuscularly or intradermally. These preparations can preferably be prepared by mixing the compound with water and making the resulting solution sterile and isotonic with the blood. In general, injectable compositions according to the invention comprise from 0.1 to 5% by weight 15 of the active compound. Suitable pharmaceutical compositions for rectal administration are preferably present as individual dose suppositories. These can be prepared by mixing a compound according to formula I with one or more 20 conventional solid excipients, for example cocoa butter, and molding the resulting mixture. Suitable pharmaceutical compositions for topical use on the skin are preferably present as an ointment, cream, lotion, paste, spray, aerosol or 25 oil. Excipients which can be used are vaseline, lanolin, polyethylene glycols, alcohols and combinations of two or more of these substances. The active compound is generally present at a concentration of from 0.1 to 15% by weight of the composition, for example from 0.5 to 2%. 30 Transdermal administration is also possible. Suitable pharmaceutical compositions for transdermal uses can be present as individual plasters which are suitable for long-term intimate contact with the epidermis of the patient. Such plasters expediently contain the active compound in an aqueous solution, which is, where appropriate, buffered, dissolved and/or 35 dispersed in an adhesive or dispersed in a polymer. A suitable active compound concentration is from approx. 1% to 35%, preferably from approx. 3% to 15%. As a particular possibility, the active compound can, as described, for example, in Pharmaceutical Research, 2(6): 318 (1986), be released by means of electrotransport or iontophoresis. 12 The compound(s) of the formula (I) can also be administered in combination with other active compounds. The following are suitable for use as additional active compounds for the combination preparations: All antidiabetics which are named in the Rote Liste [Red List] 2001, 5 Chapter 12. They can be combined with the compounds according to the invention of the formula I, particularly for improving the effect synergistically. The active compound combination can be administered either by administering the active compounds separately to the patient or in the form of combination preparations in which several active compounds 10 are present in one pharmaceutical preparation. Most of the active compounds which are listed below are disclosed in USP Dictionary of USAN and International Drug Names, US Pharmacopeia, Rockville 2001. Antidiabetics include insulin and insulin derivatives, such as Lantus® (see www.lantus.com) or HMR 1964, rapidly acting insulins (see US 6,221,633), 15 GLP-1 derivatives, such as those which were disclosed in WO 98/08871 by Novo Nordisk A/S, and hypoglycemic active compounds which are effective orally. The hypoglycemic active compounds which are effective orally preferably include sulfonylureas, biguanidines, meglitinides, oxadiazolidinediones, 20 thiazolidinediones, glucosidase inhibitors, glucagon antagonists, GLP-1 agonists, calcium channel openers, such as those which were disclosed by Novo Nordisk A/S in WO 97/26265 and WO 99/03861, insulin sensitizers, inhibitors of liver enzymes which are involved in stimulating gluconeogenesis and/or glycogenosis, modulators of glucose uptake, 25 compounds, such as antihyperlipidemic active compounds and antilipidemic active compounds, which alter fat metabolism, compounds which decrease the intake of foodstuffs, agonists of PPAR and PXR, and active compounds which act on the ATP-dependent potassium channel of the beta cells. 30 35 In one embodiment of the invention, the compounds of the formula I are administered in combination with an HMGCoA reductase inhibitor, such as simvastatin, fluvastatin, pravastatin, lovastatin, atorvastatin, cerivastatin or rosuvastatin. In one embodiment of the invention, the compounds of the formula I are administered in combination with a cholesterol absorption inhibitor, such as ezetimibe, tiqueside or pamaqueside. Intellectual Property Office of N.Z. - 7 JUN 2005 -7 FEB 2005 received 13 In one embodiment of the invention, the compounds of the formula I are administered in combination with a PPAR gamma agonist, such as rosiglitazone, pioglitazone, JTT-501 or Gl 262570. In one embodiment of the invention, the compounds of the formula I are administered in combination with a PPAR alpha agonist, such as GW 9578 or GW 7647. In one embodiment of the invention, the compounds of the formula I are administered in combination with a mixed PPAR alpha/gamma agonist, such as GW 1536, AVE 8042, AVE 8134 or AVE 0847, or as described in PCT/US00/11833, PCT/US00/11490 or DE10142734.4 (equivalent to NZ 531440). In one embodiment of the invention, the compounds of the formula I are administered in combination with a fibrate, such as fenofibrate, clofibrate or bezafibrate. In one embodiment of the invention, the compounds of the formula I are administered in combination with an MTP inhibitor, such as implitapide, BMS-201038 or R-103757. In one embodiment of the invention, the compounds of the formula I are administered in combination with a bile acid absorption inhibitor (see, for example, US 6,245,744 or US 6,221,897), such as HMR 1741. In one embodiment of the invention, the compounds of the formula I are administered in combination with a CETP inhibitor, such as JTT-705. In one embodiment of the invention, the compounds of the formula I are administered in combination with a polymeric bile acid adsorber, such as cholestyramine or colesevelam. In one embodiment of the invention, the compounds of the formula I are administered in combination with an LDL receptor inducer (see US 6,342,512), such as HMR1171 or HMR1586. In one embodiment of the invention, the compounds of the formula I are administered in combination with an ACAT inhibitor, such as avasimibe. 14 In one embodiment of the invention, the compounds of the formula I are administered in combination with an antioxidant, such as OPC-14117. In one embodiment of the invention, the compounds of the formula I are 5 administered in combination with a lipoprotein lipase inhibitor, such as NO-1886. In one embodiment of the invention, the compounds of the formula I are administered in combination with an ATP citrate lyase inhibitor, such as 10 SB-204990. In one embodiment of the invention, the compounds of the formula I are administered in combination with a squalene synthetase inhibitor, such as BMS-188494. 15 In one embodiment of the invention, the compounds of the formula I are administered in combination with a lipoprotein(a) antagonist, such as Cl-1027 or nicotinic acid 20 In one embodiment of the invention, the compounds of the formula I are administered in combination with a lipase inhibitor, such as orlistat. In one embodiment of the invention, the compounds of the formula I are administered in combination with insulin. 25 In one embodiment, the compounds of the formula I are administered in combination with a sulfonylurea, such as tolbutamide, glibenclamide, glipizide or glimepiride. In one embodiment, the compounds of the formula I are administered in combination with a biguanide, such as metformin. 30 In yet another embodiment, the compounds of the formula I are administered in combination with a meglitinide, such as repaglinide. In one embodiment, the compounds of the formula I are administered in combination with a thiazolidinedione, such as troglitazone, ciglitazone, 35 pioglitazone, rosiglitazone or the compounds which are disclosed by Dr. Reddy's Research Foundation in WO 97/41097, in particular 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinylmethoxy]phenyl]methyl]-2,4-thiazolidinedione. In one embodiment, the compounds of the formula I are administered in 15 combination with an a-glucosidase inhibitor, such as miglitol or acarbose. In one embodiment, the compounds of the formula I are administered in combination with an active compound which acts on the ATP-dependent potassium channel of the beta cells, such as tolbutamide, glibenclamide, 5 glipizide, glimepiride or repaglinide. In one embodiment, the compounds of the formula I are administered in combination with more than one of the abovementioned compounds, for example in combination with a sulfonylurea and metformin, a sulfonylurea and acarbose, repaglinide and metformin, insulin and a sulfonylurea, insulin 10 and metformin, insulin and troglitazone, insulin and lovastatin, etc. In another embodiment, the compounds of the formula I are administered in combination with CART modulators (see "Cocaine-amphetamine-regulated transcript influences energy metabolism, anxiety and gastric emptying in 15 mice" Asakawa, A, et al., M.:Hormone and Metabolic Research (2001), 33(9), 554-558), NPY antagonists, e.g. naphthalene-1 -sulfonic acid {4-[(4-aminoquinazolin-2-ylamino)methyl]cyclohexylmethyl}amide hydrochloride (CGP 71683A)), MC4 agonists (e.g. 1-amino-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid [2-(3a-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-20 hexahydropyrazolo[4,3-c]pyridin-5-yl)-1-(4-chlorophenyl)-2-oxoethyl]amide; (WO 01/91752)), orexin antagonists (e.g. 1-(2-methylbenzoxazol-6-yl)- 3-[1,5]naphthyridin-4-ylurea hydrochloride (SB-334867-A)), H3 agonists (3-cyclohexyl-1-(4,4-dimethyl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-propan-1-one oxalic acid salt (WO 00/63208)); TNF agonists, CRF 25 antagonists (e.g. [2-methyl-9-(2,4,6-trimethylphenyl)-9H-1,3,9-triazafluoren- 4-yl]dipropylamine (WO 00/66585)), CRF BP antagonists (e.g. urocortin), urocortin agonists, p3-agonists (e.g. 1-(4-chloro-3-methanesulfonylmethyl-phenyl)-2-[2-(2,3-dimethyl-1H-indol-6-yloxy)ethylamino]ethanol hydrochloride (WO 01/83451)), MSH (melanocyte-stimulating hormone) agonists, 30 CCK-A agonists (e.g. {2-[4-(4-chloro-2,5-dimethoxyphenyl)- 5-(2-cyclohexylethyl)thiazol-2-ylcarbamoyl]-5,7-dimethylindol-1-yl}acetic acid trifluoroacetic acid salt (WO 99/15525)); serotonin reuptake inhibitors (e.g. dexfenfluramines), mixed sertonin compounds and noradrenergic compounds (e.g. WO 00/71549), 5HT agonists, e.g. 1-(3-ethylbenzofuran- 35 7-yl)piperazine oxalic acid salt (WO 01/09111), bombesin agonists, galanin antagonists, growth hormone (e.g. human growth hormone), growth hormone-releasing compounds (tert-butyl 6-benzyloxy-1-(2-diisopropyl-aminoethylcarbamoyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate (WO 01/85695)), TRH agonists (see, for example, EP 0 462 884) 16 uncoupling protein 2- or 3-modulators, leptin agonists (see, for example, Lee, Daniel W.; Leinung, Matthew C.; Rozhavskaya-Arena, Marina; Grasso, Patricia. Leptin agonists as a potential approach to the treatment of obesity. Drugs of the Future (2001), 26(9), 873-881), DA agonists 5 (bromocriptine, doprexin), lipase/amylase inhibitors (e.g. WO 00/40569), PPAR modulators (e.g. WO 00/78312), RXR modulators or TR p-agonists. In one embodiment of the invention, the additional active compound is leptin; see, e.g., "Perspectives in the therapeutic use of leptin", Salvador, 10 Javier; Gomez-Ambrosi, Javier; Fruhbeck, Gema, Expert Opinion on Pharmacotherapy (2001), 2(10), 1615-1622. In one embodiment, the additional active compound is dexamphatamine or amphetamine. 15 In one embodiment, the additional active compound is fenfluramine or dexfenfluramine. In yet another embodiment, the additional active compound is sibutramine. In one embodiment, the additional active compound is orlistat. In one embodiment, the additional active compound is mazindol or 20 phentermine. In one embodiment, the compounds of the formula I are administered in combination with bulk materials, preferably insoluble bulk materials (see, e.g., Carob/Caromax® (Zunft H J; et al., Carob pulp preparation for 25 treatment of hypercholesterolemia, ADVANCES IN THERAPY (2001 Sep-Oct), 18(5), 230-6), Caromax is a carob-containing product from Nutrinova, Nutrition Specialties & Food Ingredients GmbH, Industriepark Hochst, 65926 Frankfurt/Main)). The combination with Caromax® can be effected in one preparation or by administering compounds of the formula I and 30 Caromax® separately. In this connection, Caromax® can also be administered in the form of foodstuffs, such as in bakery products or muesli bars. It will be understood that each suitable combination of the compounds 35 according to the invention with one or more of the abovementioned compounds and, as desired, one or more further pharmacologically active substances, is regarded as coming within the protective scope of the present invention. 17 jtt-705 no-1886 9a sb-204990 h0 h3c h3c ch3 oh The examples which are adduced below serve to explain the invention without, however, limiting it. # • 18 Table 1: Examples of the formula I R3 R8-. R7 O O r^t R11 -R4 yM R9 R10 N N I I R6 R1 R2 R5 Ex. R7, R8, R9, R10 R1 R2 R3 R4 R5 R6 Connection R11 MS * ;1 ;4-CI, 2-F, H, H ;H ;H ;H ;H ;H ;H ;C-2 ;OH ;ok ;2 ;2-CI, 4-F, 5-F, H ;H ;H ;H ;H ;H ;H ;C-2 ;OH ;ok ;3 ;2-CI, 4-F, 5-F, H ;H ;H ;3-H ;4-H ;5-NHCOCH3 ;6-H ;C-2 ;OH ;ok ;4 ;2-CI, 4-F, 5-F, H ;H ;H ;3-H ;4-H ;5-NHCOCOOH ;6-H ;C-2 ;OH ;ok ;5 ;2-CI, 4-F, 5-F, H ;H ;H ;3-H ;4-H ;5-NHCOCH2COOH ;6-H ;C-2 ;OH ;ok ;6 ;2-CI, 4-F, 5-F, H ;H ;H ;3-H ;4-H ;5-NHCO(CH2)2COOH ;6-H ;C-2 ;OH ;ok ;7 ;2-CI, 4-F, 5-F, H ;H ;H ;3-H ;4-COOH ;5-H ;6-H ;C-2 ;OH ;ok ;8 ;2-CI, 4-F, 5-F, H ;H ;H ;2-CI ;3-H ;4-H ;6-H ;C-5 ;OH ;ok ;# • ;19 ;9 ;4-ci, 2-f, h, h h ;h ;2-ci ;3-h ;4-h ;6-h c-5 ;oh ok ;10 ;2-ci, 4-f, 5-f, h h ;h ;3-h ;4-h ;5-h ;6-h c-2 ;OCH3 ;ok ;11 ;2-ci, 4-f, 5-f, h h ;h ;3-h ;4-COOCH3 ;5-h ;6-h c-2 ;och3 ;ok ;12 ;2-ci, 4-f, 5-f, h h ;h ;3-h ;4-cooh ;5-h ;6-h c-2 ;OCH3 ;ok ;13 ;2-ci, 4-f, 5-f, h h ;h h ;h h ;h c-2 ;n(ch3)2 ;ok ;14 ;2-ci, 4-f, 5-f, h h ;h h ;h h ;h c-2 ;nh2 ;ok ;* The information "MS is Ok" is understood as meaning that a mass spectrum or HPLC/MS was measured and the molar peak (molar mass + H+) was detected in this spectrum. 20 The compounds of the formula I are characterized by advantageous effects on sugar metabolism; in particular, they lower the blood sugar level and are suitable for treating type 2 diabetes. The compounds can therefore be used on their own or in combination with other blood sugar-lowering active 5 compounds (antidiabetics). The compounds of formula I are furthermore suitable for treating late damage in diabetes, such as nephropathy, retinopathy, neuropathy and cardiac infarction, myocardial infarction, peripheral arterial occlusion diseases, thromboses, arteriosclerosis, syndrome X, obesity, 10 inflammations, immune diseases, autoimmune diseases, such as AIDS, asthma, osteoporosis, cancer, psoriasis, Alzheimer's disease, schizophrenia and infectious diseases. The activity of the compounds was tested as follows: 15 Glycogen phosphorylase a activity test The effect of compounds on the activity of the active form of glycogen phosphorylase (GPa) was measured in the reverse direction by monitoring 20 the synthesis of glycogen from glucose 1-phosphate by determining the release of inorganic phosphate. All the reactions were carried out as duplicate determinations in 96-well microtiter plates (Half Area Plates, Costar No. 3696), with the change in absorption due to the formation of the reaction product being measured, at the wavelength specified below, in a 25 Multiscan Ascent Elisa Reader (Lab Systems, Finland). In order to measure the enzymic activity of GPa in the reverse direction, the conversion of glucose 1-phosphate into glycogen and inorganic phosphate was measured in accordance with the general method of Engers et al. (Engers HD, Shechosky S, Madsen NB, Can J Biochem 1970 Jul;48(7): 746-754) 30 but with the following modifications: Human glycogen phosphorylase a (for example containing 0.76 mg of protein/ml (Aventis Pharma Deutschland GmbH), dissolved in buffer solution E (25 mM p-glycerophosphate, pH 7.0, 1 mM EDTA and 1 mM dithiothreitol), was diluted with buffer T (50 mM Hepes, pH 7.0, 100 mM KCI, 2.5 mM EDTA, 2.5 mM MgCl2-6H20), and 35 addition of 5 mg of glycogen/ml, to a concentration of 10 pg of protein/ml. Test substances were prepared as a 10 mM solution in DMSO and diluted down to 50 ijM with buffer solution T. 10 |jl of 37.5 mM glucose, dissolved in buffer solution T and 5 mg/ml of glycogen, and also 10 pi of a solution of human glycogen phosphorylase a (10 pg of protein/ml) and 20 pi of 21 glucose 1-phosphate, 2.5 mM, were added to 10 ml of the solution. The basal value of the activity of the glycogen phosphorylase a in the absence of test substance was determined by adding 10 pi of buffer solution T (0.1% DMSO). The mixture was incubated at room temperature for 5 40 minutes and the inorganic phosphate which was released was measured using the general method of Drueckes et al. (Drueckes P, Schinzel R, Palm D, Anal Biochem 1995 Sep 1;230(1):173-177) but with the following modifications: 50 pi of a stop solution of 7.3 mM ammonium molybdate, 10.9 mM zinc acetate, 3.6% ascorbic acid, 0.9% SDS are 10 added to 50 pi of the enzyme mixture. After 60 minutes of incubation at 45°C, the absorption was measured at 820 nm. In order to determine the background absorption, the stop solution was added immediately after adding the glucose 1-phosphate solution in a separate assay. This test was carried out using a 10 pM concentration of the test substance in order to 15 determine the respective inhibition of glycogen phosphorylase a by the test substance in vitro. Table 2: Biological activity Ex. % inhibition at 10 pM 1 100 2 101 3 95 4 95 5 96 6 92 7 96 Ex. % inhibition at 10 pM 8 96 9 84 10 83 11 91 12 104 13 91 14 90 20 It can be seen from the table that the compounds of the formula I inhibit the activity of glycogen phosphorylase a and are therefore well suited for lowering the blood sugar level. They are thus particularly suitable for the prevention and treatment of type 2 diabetes. 25 The preparation of some examples is described in detail below; The remaining compounds of formula I were obtained in an analogous manner: 22 Example 2: 3-{2-[3-(2-Chloro-4,5-difluorobenzoyl)ureido]phenyl}acrylic acid a) 2-Chloro-4,5-difluorobenzoyl isocyanate 5 2-Chloro-4,5-difluorobenzamide was dissolved in dichloromethane, after which 1.5 eq. of oxalyl chloride were added and the mixture was heated to reflux for 16 hours. The reaction mixture was then concentrated under high vacuum and used in step b without any further purification. 10 b) 3-{2-[3-(2-Chloro-4,5-difluorobenzoyl)ureido]phenyl}acrylic acid 0.76 g (3.5 mmol) of 2-chloro-4,5-difluorobenzoyl isocyanate from step a in 6 ml of acetonitrile were added to 0.41 g (2.5 mmol) of 15 3-(2-aminophenyl)acrylic acid and the mixture was reacted for 2 hours at 40°C. After the mixture has cooled down to room temperature, the precipitate is filtered off with suction, washed twice with acetonitrile, sucked dry and dried. 0.72 g (76%) of the desired product is obtained. m.p.: 188.5, decomposition 20 Examples 1, 8, 9 and 10 were prepared from the corresponding aminoacrylic acids and the corresponding isocyanates in analogy with Example 2. 25 Example 3: 3-{4-Acetylamino-2-[3-(2-chloro-4,5-difluorobenzoyl)ureido]phenyl}acrylic acid a) Methyl 3-{2-[3-(2-chloro-4,5-difluorobenzoyl)ureido]-4-nitrophenyl}-30 acrylate 1,0 g (4.5 mmol) of methyl 3-(2-amino-4-nitrophenyl)acrylate (prepared by nitrating methyl 3-(2-aminophenyl)acrylate with urea nitrate in conc. sulfuric acid) were reacted with 0.98 g (4.5 mmol) of 2-chloro-4,5-difluorobenzoyl 35 isocyanate (example 2 a) in 6 ml of acetonitrile, and the reaction mixture was stirred at room temperature for 30 minutes. The precipitate was filtered off with suction, washed with diethyl ether and dried. 1.9 g (96%) of the desired product were obtained. 23 b) Methyl 3-{4-amino-2-[3-(2-chloro-4,5-difluorobenzoyl)ureido]phenyl}-acrylate 1,9 g (4.3 mmol) of methyl 3-{2-[3-(2-chloro-4,5-difluorobenzoyl)ureido]-5 4-nitrophenyl}acrylate were heated to boiling temperature in 100 ml of ethyl acetate and 4.86 g (21.6 mmol) of SnCh monohydrate were then added. After an hour, the mixture was allowed to cool down to room temperature and adjusted to pH 8 using a 10% solution of sodium hydrogen carbonate. The resulting precipitate was filtered off with suction and washed with 10 methanol. The organic phase was washed twice with H20, dried and concentrated in vacuo. The resulting product was used in step c without any further purification. c) Methyl 3-{4-acetylamino-2-[3-(2-chloro-4,5-difluorobenzoyl)ureido]-15 phenyljacrylate 6 ml of N-methylpyrrolidone, 1.11 g (3.4 mmol) of cesium carbonate and 0.27 g (3.4 mmol) of acetyl chloride were added to 0.70 g (1.7 mmol) of methyl 3-{4-amino-2-[3-(2-chloro-4,5-difluorobenzoyl)ureido]phenyl}acrylate 20 and the mixture was stirred at room temperature for 30 minutes. It was then diluted with H2O and extracted with ethyl acetate. The organic phase was washed with H2O, dried and concentrated. 0.65 g (85%) of the desired product was obtained. 25 d) 3-{4-Acetylamino-2-[3-(2-chloro-4,5-difluorobenzoyl)ureido]phenyl}-acrylic acid 0.65 g (1.4 mmol) of methyl 3-{4-acetylamino-2-[3-(2-chloro-4,5-difluoro-benzoyl)ureido]phenyl}acrylate was dissolved in 8 ml of tetrahydrofuran, 30 and 8 ml of H20 and 0.17 g (7.2 mmol) of lithium hydroxide were added. After 15 hours at room temperature, the mixture was made acid with 2 N hydrochloric acid and extracted with ethyl acetate. The organic phase was dried, concentrated and stirred up with diethyl ether. The resulting precipitate was filtered off with suction and yielded 77 mg (13%) of the 35 desired product. M.p.: 196°C, decomposition 24 Example 7: 4-[3-(2-Chloro-4,5-d ifluorobenzoyl )u reido]-3-(2-methoxycarbonyl vinyl )-benzoic acid 5 0.22 g (0.5 mmol) of methyl 4-[3-(2-chloro-4,5-difluorobenzoyl)ureido]-3-(2-methoxycarbonylvinyl)benzoate (example 11 c) were dissolved in 10 ml of THF, after which 10 ml of H2O and 0.06 g (2.4 mmol) of lithium hydroxide were added. After 2 hours, the mixture was made acid with 2 N hydrochloric acid; this was then followed by extraction with ethyl acetate 10 and concentration. Following preparative HPLC (column: Waters Xterra™MS C18, 5 pm, 30x100 mm, mobile phase: A: H20 + 0.2% trifluoroacetic acid, B: acetonitrile, gradient: 2.5 minutes 90% A/10% B to 17.5 minutes 10% A/90% B), 0.02 g (10%) of the desired product was obtained. 15 M.p.: 99°C Example 11: Methyl 4-[3-(2-chloro-4,5-difluorobenzoyl)ureido]-3-(2-methoxycarbonyl-vinyl)benzoate 20 a) Methyl 4-amino-3-iodobenzoate 10.4 g (68.8 mmol) of methyl 4-aminobenzoate were dissolved in 100 ml of acetic acid and 11.17 g (68.8 mmol) of iodine monochloride in 100 ml of 25 acetic acid were added. In connection with this, the reaction temperature rose to 30°C. After an hour at room temperature, the mixture was poured onto a 10% solution of sodium hydrogen carbonate and the whole was extracted with dichloromethane; the organic phase was dried and concentrated. 14 g (73%) of the desired product were obtained. 30 b) Methyl 4-amino-3-(2-methoxycarbonylvinyl)benzoate 0.5 g (1.8 mmol) of methyl 4-amino-3-iodobenzoate, 1.1 eq. of methyl acrylate, 2.5 eq. of cesium carbonate, 1 eq. of (nBu)4NHS04, 0.1 eq. of 35 triphenyl phosphine, 0.1 eq. of palladium acetate, 2 ml of acetonitrile and 2 ml of H20 were heated, for 5 minutes under an argon atmosphere, in a microwave at 120°C and 140 watts. Ethyl acetate was added to the reaction mixture and the whole was washed with H2O, dried and 25 concentrated. This resulted in 0.3 g (71%) of the desired product, which was reacted in step c without any further purification. c) Methyl 4-[3-(2-chloro-4,5-difluorobenzoyl)ureido]-3-(2-methoxycarbonyl-5 vinyl)benzoate Methyl 4-amino-3-(2-methoxycarbonylvinyl)benzoate was prepared from methyl 4-amino-3-(2-methoxycarbonylvinyl)benzoate and 2-chloro-4,5-difluorobenzoyl isocyanate in analogy with example 3a. 10 M.p.: 183°C Example 12: a) 4-Amino-3-iodobenzoic acid 15 1.73 g (43.4 mmol) of sodium hydroxide in 100 ml of methanol and 100 ml of H20 were added to 6.0 g (21.7 mmol) of methyl 4-amino-3-iodobenzoate and the mixture was stirred at room temperature for 16 hours. It was made to pH 9 with 2 N hydrochloric acid and extracted with ethyl acetate. The 20 organic phase was dried and concentrated. 5.1 g (89%) of the desired product were obtained. b) 4-Amino-3-(2-methoxycarbonylvinyl)benzoic acid 25 0.5 g (1.9 mmol) of 4-amino-3-iodobenzoic acid, 0.18 g (2.1 mmol) of methyl acrylate, 1.54 g (4.8 mmol) of cesium carbonate, 0.64 g (1.9 mmol) of (nBu)4NHS04, 0.05 g (0.2 mmol) of triphenyl phosphine and 0.04 g (0.2 mmol) of palladium acetate, 1.5 ml of acetonitrile and 1.5 ml of H20 were heated, for 5 minutes under an argon atmosphere, in a microwave at 30 120°C and 140 watts. Ethyl acetate was added to the reaction mixture and the whole was washed with H20, dried and concentrated. The crude product was reacted in step c without any further purification. c) 4-[3-(2-Chloro-4,5-difluorobenzoyl)ureido]-3-(2-methoxycarbonylvinyl)-35 benzoic acid 4-Amino-3-(2-methoxycarbonylvinyl)benzoic acid was reacted with 2-chloro-4,5-difluorobenzoyl isocyanate, in analogy with example 2 b, to give the desired product. </div>

Claims

M.p.:216°C WO 03/104188 Patent Claims: 27 PCT7EP03/05355

1. A compound of the formula I, O. R11 R8 I I R6 R5 yX R1 R2 R9 R10 in which R7, R8, R9 and R10 are, independently of each other, H, F, CI, Br, OH, N02, CN, 0-(CrC6)-alkyl, 0-(C2-C6)-alkenyl, 0-(C2-C6)-alkynyl, 0-S02-(CrC4)-alkyl, (Ci-C6)-alkyl, (C2-C6)-alkenyl or (C2-C6)-alkynyl, where alkyl, alkenyl and alkynyl can be substituted, more than once, by F, CI or Br; R1 and R2 are, independently of each other, H, (CrC6)-alkyl, where alkyl can be substituted by OH, 0-(CrC4)-alkyl, NH2, NH(CrC4)-alkyl or NKCt-CeJ-alkylfe, 0-(CrC6)-alkyl, CO-(CrC6)-alkyl, COO-(CrC6)-alkyl, (CrC6)-alkylene-COOH, (CrC6)-alkylene-COO-(CrC6)-alkyl; R3, R4, R5 and R6 are, independently of each other, H, F, CI, Br, N02, CN, 0-R12, S-R12, COOR12, N(R13)(R14), N(R13)COR15, (CrC6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, (C3-C7)-cycloalkyl or (C3-C7)-cycloalkyl-(CrC4)-alkylene, where alkyl, cycloalkyl, alkylene, alkenyl and alkynyl can be substituted, more than once, by F, CI, Br, OR12, COOR12 or N(R16)(R17); R11 is 0-R12 or N(R18)(R19); R12 is H, (CrC8)-alkyl, (C2-Ca)-alkenyl, (C2-C8)-alkynyl, where alkyl, alkenyl and alkynyl can be substituted, more than once, 28 by F, CI, Br, OH or 0-(Ci-C4)-alkyl; Intellectual Property Office of N.Z. - 7 JUN 2005 received 10 15 R13 and R14are, independently of each other, H, (CrC8)-alkyl, (C2-C8)-alkenyl, (C2-C8)-alkynyl, (C3-C7)-cycloalkyl, (C3-C7)-cycloalkyl-(Ci-C4)-alkylene, COO-(CrC4)-alkyl, COO-(C2-C4)-alkenyl, phenyl or S02-phenyl, where the phenyl ring can be substituted, up to two times, by F, CI, CN, OH, (Ci-C6)-alkyl, 0-(Ci-C6)-alkyl, CF3, OCF3, COOH, COO-(Ci-C6)-alkyl or CONH2; or the radicals R13 and R14 form, with the nitrogen atom to which they are bonded, a 3-7-membered, saturated heterocyclic ring which can contain up to 2 further heteroatoms from the group N, O or S, where the heterocyclic ring can be substituted, up to three times, by F, CI, Br, OH, Oxo, N(R20)(R21) or (C-i-C4)-alkyl; R16 and R17are, independently of each other, H, (CrC8)-alkyl, (C2-C8)-alkenyl, (C2-C8)-alkynyl, (C3-C7)-cycloalkyl, (C3-C7)-cycloalkyl-20 (CrC4)-alkylene, COO-(CrC4)-alkyl, COO-(C2-C4)-alkenyl, phenyl or S02-phenyl, where the phenyl ring can be substituted, up to two times, by F, CI, CN, OH, (CrC6)-alkyl, 0-(CrC6)-alkyl, CF3, OCF3, COOH, COO-(CrC6)-alkyl or CONH2; 25 or the radicals R16 and R17 form, with the nitrogen atom to which they are bonded, a 3-7-membered, saturated heterocyclic ring which can contain up to 2 further heteroatoms from the group N, O or S, where the heterocyclic ring can be substituted, up to 30 three times, by F, CI, Br, OH, Oxo, N(R20)(R21) or (CrC4)- alkyl; R18, R19 are, independently of each other, H, (Ci-C8)-alkyl, (C2-C8)-alkenyl, (C2-C8)-alkynyl, (C3-C7)-cycloalkyl, (C3-C7)-cycloalkyl-35 (C-i-C4)-alkylene, COO-(Ci-C4)-alkyl, COO-(C2-C4)-alkenyl, phenyl or S02-phenyl, where the phenyl ring can be substituted, up to two times, by F, CI, CN, OH, (Ci-C6)-alkyl, 0-(CrC6)-alkyl, CF3, OCF3, COOH, COO-(Ci-C6)-alkyl or CONH2; 29 or the radicals R18 and R19, together with the nitrogen atom to which they are bonded, form a 3-7-membered, saturated heterocyclic ring which can contain up to 2 further heteroatoms from the group N, O or S, where the heterocyclic ring can be substituted, up 5 to three times, by F, CI, Br, OH, Oxo, N(R20)(R21) or (CrC4)-alkyl; R15 is (Ci-CeJ-alkyl, (Ca-CeJ-alkenyl, (C2-Cg)-alkynyl, (C3-Cr)-cyclo- alkyl, (Cs-CzJ-cycloalkyHCi-C^alkylene, where alkyl, 10 cycloalkyl, alkylene, alkenyl and alkynyl can be substituted more than once by F, NH2, NH(Ci-C4)-alkyl, N[(Ci-C4)-alkyi]2l OH, 0-(Ci-C4)-alkyl, 0-(C2-C4)-alkenyl) or 0-C0-(Ci-C4)-alkyl, COOR12, CON(R13){R14), heteroaryl, (C6-Ci0)-aryl or (C6-Cio)-aryl-(Ci-C4)-alkylene, where heteroaryl and aryl can 15 be substituted by 0-(Ci-C4)-alkyl, where alkyl can be substituted more than once by F or CI; R20 and R21 are, independently of each other, H, (CrCaJ-alkyl, (C2-C8)-alkenyl, (C2-C8)-alkynyl, (C3-C/)-cycloalkyl, (C3-C7)-cycloalkyl-20 (CrC4)-alkylene, COO-(CrC4)-alkyl, COO-(C2-C4)-alkenyl1 phenyl or S02-phenyl, where the phenyl ring can be substituted, up to two times, by F, CI, CN, OH, (Ci-C6)-alkyl, 0-(Ci-C6)-alkyl, CF3, OCF3, COOH, COO-(Ci-C6)-alkyl or CONH2; 25 30 35 30 and the physiologically tolerated salts thereof.

2. A compound of formula I as claimed in claim 1 wherein R7, R8, R9 and R10 are, independently of each other, H, F, CI, Br, OH, N02, CN, 0-(Ci-C6)-alkyl, 0-(C2-C6)-alkenyl, 0-(C2-C6)-alkynyl, 0-S02-(CrC4)-alkyl, (Ci-C6)-alkyl, (C2-Ce)-alkenyl, (C2-C6)-alkynyl, where alkyl, alkenyl and alkynyl can be substituted, more than once, by F, CI or Br; R1 and R2 are H; R3, R4, R5 and R6 are, independently of each other, H, F, CI, Br, N02, CN, 0-R12, S-R12, COOR12, N(R13)(R14), N(R13)COR15, (Ci-C6)-alkyl, (C^QsJ-alkenyl, (C2-C6)-alkynyl, (C3-C7)-cycloalkyl or (C3-C7>-cycloalkyl-(CrC4)-alkylene, where alkyl, cycloalkyl, alkylene, alkenyl and alkynyl can be substituted, more than once, by F, CI, Br, OR12, COOR12 or N(R16)(R17); is 0-R12, or N(R18)(R19); is H, (Ci-C8)-alkyl, (C2-C8)-alkenyi, (C2-C8)-alkynyl, where alkyl, alkenyl and alkynyl can be substituted, more than once, by F, CI, Br, OH or 0-(Ci-C4)-alkyI; R13and R14 are, independently of each other, H, (Ci-C8)-alkyl, (C2-C8)-alkenyl, (C2-C8)-alkynyl, (C3-C7)-cycloalkyl, (C3-C7)-cycloalkyl-(Ci-C4)-alkylene, COO-(Ci-C4)-alkyl, COO-(C2-C4)-alkenyl, phenyl or S02-phenyl, where the phenyl ring can be substituted, up to two times, by F, CI, CN, OH, (Ci-C6)-alkyl, 0-(CrC6)-alkyl, CF3, OCF3, COOH, COO-(Ci-C6)-alkyl or CONH2; or the radicals R13 and R14 form, with the nitrogen atom to which they are bonded, a 3-7-membered, saturated heterocyclic ring which can contain up to 2 further heteroatoms from the group N, O or S, where the heterocyclic ring can be substituted, up to three times, by F, CI, Br, OH, Oxo, N(R20)(R21) or (Ci-C4)- Intellectual Property Office of N.Z. -7 JUN 2005 received R11 R12 31 alkyl; R16 and R17are, independently of each other, H, (CrC8)-alkyl, (C2-C8)-alkenyl, (C2-C8)-alkynyl, (C3-C7)-cycloalkyl, (C3-C7)-cycloalkyl-5 (CrC-O-alkylene, COO-(CrC4)-alkyl, COO-(C2-C4)-alkenyl, phenyl or S02-phenyl, where the phenyl ring can be substituted, up to two times, by F, CI, CN, OH, (Ci-C6)-alkyl, 0-(CrC6)-alkyl, CF3, OCF3, COOH, COO-(CrC6)-alkyl or CONH2; 10 or the radicals R16 and R17 form, with the nitrogen atom to which they are bonded, a 3-7-membered, saturated heterocyclic ring which can contain up to 2 further heteroatoms from the group N, O or S, where the heterocyclic ring can be substituted, up to 15 three times, by F, CI, Br, OH, Oxo, N(R20)(R21) or (C1-C4)- alkyl; R18 and R19 are, independently of each other, H, (CrC8)-alkyl, (C2-C8)-alkenyl, (C2-C8)-alkynyl, (C3-C7)-cycloalkyl, (C3-C7)-cycloalkyl-20 (CrC4)-alkylene, COO-(Ci-C4)-alkyl, COO-(C2-C4)-alkenyl, phenyl or S02-phenyl, where the phenyl ring can be substituted, up to two times, by F, CI, CN, OH, (Ci-C6>-alkyl, 0-(CrC6)-alkyl, CF3, OCF3, COOH, COO-(CrC6)-alkyl or CONH2; 25 or the radicals R18 and R19, together with the nitrogen atom to which they are bonded, form a 3-7-membered, saturated heterocyclic ring which can contain up to 2 further heteroatoms from the group N, O or S, where the heterocyclic ring can be substituted, up 30 to three times, by F, CI, Br, OH, Oxo, N(R20)(R21) or (CrC4)-alkyl; 35 Intellectual Property Office of NX - 7 JUN 2005 received. ► - 32 5 is (Ci-CsJ-alkyl, (C2-C8)-alkenyl, (C2-C8)-alkynyl, (C3-C7)-cyclo-alkyl, (C3-C7)-cycloalkyl-(Ci-C4)-alkylene, where alkyl, cycloalkyl, alkylene, alkenyl and alkynyl can be substituted more than once by F, NH2, NH(CrC4)-alkyl, N[(CrC4)-alkyl]2, OH, 0-(Ci-C4)-alkyl, 0-(C2-C4)-alkenyl) or 0-C0-(Ci-C4)-alkyl, COOR12, CON(R13)(R14), heteroaryl, (C6-Ci0)-aryl, (C6-C10)-aryl-(Ci-C4)-alkylene, where heteroaryl and aryl can be substituted by 0-(Ci-C4)-alkyl, where alkyl can be substituted more than onoe by For CI; R20 and R21 are, independently of each other, H, (Ci-C8)-alkyl, (C2-C8)-alkenyl, (C2-C8)-alkynyl, (C3-C7)-cycloalkyl, (C3-C7)-cycloalkyl-20 (CrC4)-alkylene, COO-(Ci-C4)-alkyl, COO-(C2-C4)-alkenyl, phenyl or S02-phenyl, where the phenyl ring can be substituted, up to two times, by F, CI, CN, OH, (CrC6)-alkyl, 0-(Ci-C6)-alkyl, CF3, OCF3, COOH, COO-(CrC6)-alkyl or CONH2; and the physiologically tolerated salts thereof.

3. A compound of formula I as claimed in claim 1 or 2, wherein 30 R7, R8, R9 and R10 are, independently of each other, H, F or CI; R1 and R2 are H; R3, R4, R5 and R6 are, independently of each other, H, CI, COOH, COO-35 (CrC4)-alkyl or NHCOR15; R15 10 15 R11 is 0-R12, N(R18)(R19); MtOtUftl PrOP«V Office of NX V9 SEP 2005 received. 33 R12 is H or (CrC4)-alkyl; R18 and R19are H or (Ci-C4)-alkyl; 5 R15 is (CrC4)-alkyl or COOH; and the physiologically tolerated salts thereof. 10

4. A pharmaceutical which comprises one or more of the compounds as claimed in any one of claims 1 to 3.

5. A pharmaceutical which comprises one or more of the compounds as claimed in any one of claims 1 to 3 and one or more blood sugar- 15 lowering active compounds.

6. The use of the compounds as claimed in any one of claims 1 to 3 for producing a medicament for treating type 2 diabetes. 20

7. The use of the compounds as claimed in any one of claims 1 to 3 for producing a medicament for lowering blood sugar.

8. The use of the compounds as claimed in any one of claims 1 to 3 in combination with at least one further blood sugar-lowering active 25 compound for producing a medicament for treating type 2 diabetes.

9. The use of the compounds as claimed in any one of claims 1 to 3 in combination with at least one further blood sugar-lowering active compound for producing a medicament for lowering blood sugar. 30

10. A process for producing a pharmaceutical which comprises one or more of the compounds as claimed in any one of claims 1 to 3, which comprises mixing the active compound with a pharmaceutically suitable excipient and bringing this mixture into a form which is suitable for 35 administration. Intellectual FrootjfiV Office of M.2. 2 S NOV 2005 34

11. A compound according to claim 1, substantially as herein described or exemplified.

12. A pharmaceutical according to claim 4, substantially as herein described or exemplified.

13. A pharmaceutical according to claim 5, substantially as herein described or exemplified.

14. A use according to claim 6, substantially as herein described or exemplified.

15. A use according to claim 7, substantially as herein described or exemplified.

16. A use according to claim 8, substantially as herein described or exemplified.

17. A use according to claim 9, substantially as herein described or exemplified.

18. A process according to claim 10, substantially as herein described or exemplified. Intellectual Property Office of N.2. - 7 JUN 2005 received